Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Hypertension - Tập 42 Số 6 - Trang 1206-1252 - 2003
Aram V. Chobanian1, George L. Bakris1, Henry R. Black1, William C. Cushman1, Lee A. Green1, Joseph L. Izzo1, Daniel W. Jones1, Barry J. Materson1, Suzanne Oparil1, Jackson T. Wright1, Edward J. Roccella1,2
1From Boston University School of Medicine (A.V.C.), Boston, Mass; Rush University Medical Center (G.L.B., H.R.B.), Chicago, Ill; Veterans Affairs Medical Center (W.C.C.), Memphis, Tenn; University of Michigan (L.A.G.), Ann Arbor, Mich; State University of New York at Buffalo School of Medicine (J.L.I. Jr.), Buffalo, NY; University of Mississippi Medical Center (D.W.J.), Jackson, Miss; University of Miami (B.J.M.), Miami, Fla; University of Alabama at Birmingham (S.O.), Birmingham, Ala; Case Western...
2NATIONAL INSTITUTES OF HEALTH

Tóm tắt

The National High Blood Pressure Education Program presents the complete Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Like its predecessors, the purpose is to provide an evidence-based approach to the prevention and management of hypertension. The key messages of this report are these: in those older than age 50, systolic blood pressure (BP) of greater than 140 mm Hg is a more important cardiovascular disease (CVD) risk factor than diastolic BP; beginning at 115/75 mm Hg, CVD risk doubles for each increment of 20/10 mm Hg; those who are normotensive at 55 years of age will have a 90% lifetime risk of developing hypertension; prehypertensive individuals (systolic BP 120–139 mm Hg or diastolic BP 80–89 mm Hg) require health-promoting lifestyle modifications to prevent the progressive rise in blood pressure and CVD; for uncomplicated hypertension, thiazide diuretic should be used in drug treatment for most, either alone or combined with drugs from other classes; this report delineates specific high-risk conditions that are compelling indications for the use of other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta-blockers, calcium channel blockers); two or more antihypertensive medications will be required to achieve goal BP (<140/90 mm Hg, or <130/80 mm Hg) for patients with diabetes and chronic kidney disease; for patients whose BP is more than 20 mm Hg above the systolic BP goal or more than 10 mm Hg above the diastolic BP goal, initiation of therapy using two agents, one of which usually will be a thiazide diuretic, should be considered; regardless of therapy or care, hypertension will be controlled only if patients are motivated to stay on their treatment plan. Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician’s judgment remains paramount.

Từ khóa


Tài liệu tham khảo

10.1161/01.HYP.25.3.305

10.1001/jama.290.2.199

World Health Report 2002: Reducing risks promoting healthy life. Geneva Switzerland: World Health Organization 2002. http://www.who.int/whr/2002.

10.1001/archinte.1997.00440420033005

10.1001/jama.289.19.2560

U. S. Department of Health and Human Services National Heart Lung and Blood Institute. National High Blood Pressure Education Program. Available at: http://www.nhlbi.nih.gov/about/nhbpep/index.htm. Accessed November 2003.

10.1016/S0002-9378(00)99785-0

Roccella E Kaplan N. Interpretation and evaluation of clinical guidelines. In: Izzo JL Jr Black HR (eds). Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 126–127. PR

10.1007/s11906-999-0044-3

10.1001/jama.288.15.1882

Last JM Abramson JH. A Dictionary of Epidemiology. 3rd ed. New York NY: Oxford University Press; 1995.

Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a guidebook to the medical information jungle. J Fam Pract. 1994; 39: 489–499. PR

10.1136/bmj.314.7085.947

Delbecq A Van de Ven A Gustafson D. Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Process. Glenview IL: Scott Foresman; 1975. PR

10.1161/circ.96.1.308

10.1001/jama.287.8.1003

10.1016/S0140-6736(01)06710-1

10.1016/S0140-6736(02)11911-8

10.1056/NEJMoa003417

10.1161/circ.83.1.1984895

10.1161/circ.106.25.3143

10.1161/circ.103.9.1245

10.1001/jama.1997.03550030052033

10.1001/jama.1991.03460240051027

10.1001/jama.282.6.539

10.1056/NEJMoa010273

10.1161/hyp.36.4.594

10.1111/j.1524-6175.2002.02045.x

10.1161/01.HYP.37.1.12

Hyman DJ, Pavlik VN, Vallbona C. Physician role in lack of awareness and control of hypertension. J Clin Hypertens (Greenwich). 2000; 2: 324–330.X

10.1056/NEJM199812313392701

10.1001/jama.282.21.2012

10.1001/jama.288.14.1723

Cleveland LE Goldman JD Borrud LG. Data tables: results from USDA’s 1994 continuing survey of food intakes by individuals and 1994 diet and health knowledge survey. Riverdale MD: Agricultural Research Service US Department of Agriculture. 1996.http://www.barc.usda.gov/bhnrc/foodsurvey/pdf/Tbs1994.pdf

10.1016/S0140-6736(87)90127-9

U S Department of Health and Human Services. Physical activity and health: a report of the Surgeon General. Atlanta GA: US Department of Health and Human Services Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion. 1996. http://www.cdc.gov/nccdphp/sgr/contents.htm PR

Division of Adult and Community Health National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention. 5 a day surveillance: behavioral risk factor surveillance system online prevalence data 1995–2000. Available at: http://apps.nccd.cdc.gov/5ADaySurveillance./ Accessed November 2003.

10.1161/01.hyp.17.1_suppl.i16

American Public Health Association. 2002–4 Reducing sodium content in the American diet. Association News. 2002; 5–6.

National High Blood Pressure Education Program. Summary report: the National High Blood Pressure Education Program Coordinating Committee meeting. Bethesda MD: National High Blood Pressure Education Program National Heart Lung and Blood Institute; 2002. pp. 1–37. http://www.nhlbi.nih.gov/about/nhbpep/nhbp_abs.htm

Office of Disease Prevention and Health Promotion US Department of Health and Human Services. Healthy People 2010. Available at: http://www.healthypeople.gov./ Accessed November 2003.

US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute. Facts about the DASH eating plan. Available at http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/index.htm. Accessed November 2003.

National Heart Lung and Blood Institute. Your guide to lowering high blood pressure. Available at http://www.nhlbi.nih.gov/hbp/index.html. Accessed November 2003.

US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute National High Blood Pressure Education Program. National High Blood Pressure Education Month. Available at: http://hin.nhlbi.nih.gov/nhbpep_kit./ Accessed November 2003.

US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute. The heart truth: a national awareness campaign for women about heart disease. Available at: http://www.nhlbi.nih.gov/health/hearttruth/index.htm. Accessed November 2003.

National Institutes of Health National Heart Lung and Blood Institute Office of Prevention Education and Control. Mobilizing African American communities to address disparities in cardiovascular health: The Baltimore City Health Partnership Strategy Development Workshop. Summary report. Available at: http://www.nhlbi.nih.gov/health/prof/heart/other/balt_rpt.htm. Accessed November 2003.

US Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute. NHLBI Healthy People 2010 Gateway. Available at: http://hin.nhlbi.nih.gov./ Accessed November 2003.

National Heart Lung and Blood Institute. Cardiovascular disease enhanced dissemination and utilization centers (EDUCs) awardees. Available at: http://hin.nhlbi.nih.gov/educs/awardees.htm. Accessed November 2003.

National Institutes of Health National Heart Lung and Blood Institute. Hearts N’ Parks. Available at: http://www.nhlbi.nih.gov/health/prof/heart/obesity/hrt_n_pk/index.htm. Accessed November 2003.

National Institutes of Health. Healthbeat radio network. Available at: http://radiospace.com/healthbeat.htm. Accessed November 2003.

National Heart Lung and Blood Institute. Salud para su Corazón (For the Health of Your Heart). Available at: http://www.nhlbi.nih.gov/health/prof/heart/latino/salud.htm. Accessed November 2003.

National Institutes of Health. Mad as a hatter? Join our campaign for a mercury free NIH. Available at: http://www.nih.gov/od/ors/ds/nomercury./ Accessed November 2003.

10.1001/jama.289.8.1027

Working Meeting on Blood Pressure Measurement: Summary Report. Available at: http://www.nhlbi.nih.gov/health/prof/heart/hbp/bpmeasu.pdf. Accessed November 2003.

10.1001/archinte.161.5.729

10.1161/circ.88.5.8222141

10.1097/00126097-200212000-00004

World Hypertension League. Measuring your blood pressure. Available at: http://www.mco.edu/org/whl/bloodpre.html. Accessed November 2003.

10.1016/0895-7061(95)00341-X

10.1161/01.cir.0000056521.67546.aa

Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood Pressure Monitoring. Task force V: White-coat hypertension. Blood Press Monit. 1999; 4: 333–341. PR

10.1161/hyp.35.3.844

10.1056/NEJMoa022273

10.1016/0002-8703(93)90128-V

10.1161/circ.90.2.8044959

GFR /1.73 M2 by MDRD (± SUN and SAlb) Calculator. Available at: http://www.hdcn.com/calcf/gfr.htm. Accessed November 2003.

10.7326/0003-4819-134-8-200104170-00007

10.1046/j.1523-1755.2002.00629.x

10.7326/0003-4819-130-6-199903160-00002

10.1161/hyp.35.4.898

10.1001/jama.286.4.421

10.1191/1358863x02vm412ra

10.1056/NEJMoa021993

10.1056/NEJM200003233421202

10.1007/s11883-000-0111-3

10.1053/ajkd.2002.36321

10.1111/j.1524-6175.2002.01452.x

10.1038/ki.1998.37

Pohl MA. Renovascular hypertension and ischemic nephropathy. In: Wilcox CS (ed): Atlas of Diseases of the Kidney. Philadelphia PA: Developed by Current Medicine Inc.; 1999.

Biglieri EG. Primary aldosteronism. Curr Ther Endocrinol Metab. 1997; 6: 170–172.

10.1001/archinte.1996.00440160050008

10.1016/S0092-8674(01)00241-0

10.1016/S0895-7061(00)00242-9

10.1016/S0895-7061(01)02216-6

10.1001/jama.287.13.1680

Cooper-DeHoff RM, Bristol HA, Pepine CJ. Ethnic differences in systolic blood pressure control in hypertensive patients with coronary artery disease. Am J Hypertens. 2003; 16: 27A.

10.1016/S0140-6736(98)04311-6

10.2337/diacare.26.2007.S80

10.1053/ajkd.2002.29865

10.1016/S0140-6736(00)03307-9

10.1161/hyp.35.2.539

10.1001/archinte.1997.00440270105009

10.1161/hyp.35.2.544

10.1056/NEJM200101043440101

10.7326/0003-4819-135-12-200112180-00005

10.1161/hyp.35.4.858

10.1161/hyp.35.3.838

10.7326/0003-4819-136-7-200204020-00006

10.1161/hyp.38.5.1112

Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. Writing Group of the PREMIER Collaborative Research Group. JAMA. 2003; 289: 2083–2093. RA

10.1001/jama.289.16.2073

10.1016/S0140-6736(02)08089-3

10.1056/NEJM199304013281303

10.1161/01.hyp.13.5_suppl.i36

10.1016/0140-6736(90)91908-S

Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. J Hypertens. 1996; 14: 929–933. PR

10.1001/jama.1997.03540330061036

10.1001/jama.289.19.2534

10.1001/jama.288.23.2981

10.1056/NEJM200001203420301

10.1016/S0140-6736(01)06178-5

10.1056/NEJMoa021716

10.1016/S0140-6736(97)05381-6

10.1016/S0140-6736(03)14286-9

10.1016/S0140-6736(98)05012-0

10.1016/S0140-6736(99)10327-1

10.1016/S0140-6736(00)02526-5

10.1016/S0140-6736(00)02527-7

10.1016/S0002-9343(96)00138-6

10.1161/01.hyp.15.4.348

10.1056/NEJM199406303302603

10.1016/S0002-9343(96)00268-9

10.1161/01.HYP.29.1.8

10.1001/jama.279.22.1813

10.1001/archinte.159.6.551

10.1161/hyp.35.5.1025

10.1001/archinte.1988.00380060036009

10.1001/archinte.162.20.2325

10.2165/00003495-200262030-00003

10.1136/bmj.326.7404.1427

10.1136/bmj.324.7329.71

10.1161/circ.104.24.2996

Tepper D. Frontiers in congestive heart failure: effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. Congest Heart Fail. 1999; 5: 184–185. RA

10.1056/NEJM200105313442201

10.1161/circ.90.4.7923660

10.1056/NEJM199108013250501

The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993; 342: 821–828. RA

10.1056/NEJM199512213332503

10.1056/NEJMoa010713

10.1056/NEJM199909023411001

10.1016/S1388-9842(03)00052-7

10.1016/S0735-1097(02)02848-6

10.1001/jama.1982.03320370021023

10.1056/NEJM199209033271001

10.1016/S0140-6736(00)04560-8

10.1056/NEJMoa030207

10.1001/jama.290.21.2805

10.1136/bmj.317.7160.713

10.1056/NEJM199311113292004

10.1056/NEJMoa011161

10.1056/NEJMoa011303

10.1016/S0140-6736(96)11445-8

10.1001/archinte.162.14.1636

Rosendorff C. Treatment of hypertension patients with ischemic heart disease. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 456–459. PR

10.1001/archinte.159.17.2004

Chrysant GS Oparil S. Treatment of hypertension in the patient with cardiovascular disease. In: Antman EM (ed): Cardiovascular Therapeutics: A Companion to Braunwald’s Heart Disease. Philadelphia PA: WB Saunders; 2001. pp. 768–795. PR

10.1016/S0735-1097(01)01567-4

10.1056/NEJMoa020265

American Heart Association. Heart disease and stroke statistics-2003 update. Dallas TX: American Heart Association; 2002.

10.1056/NEJM199702203360801

10.2337/diacare.23.9.1278

Prevalence of Diabetes and Impaired Fasting Glucose in Adults-United States, 1999–2000. Morbidity and Mortality Weekly Report. 2003; 52: 833–837.

Collins AJ, Kasiske B, Herzog C, Chen S-C, Everson S, Constantini E, et al. Excerpts from the United States Renal Data System 2001 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Am J Kidney Dis. 2001; 38: S7–S247.

10.2337/diacare.25.2007.S85

10.1053/ajkd.2000.16225

10.1056/NEJM199807233390404

Assman G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J. 1998; 19: A2–A11. F

10.1001/archinte.159.10.1033

10.1001/archinte.159.10.1097

10.1161/circ.100.10.1134

10.1161/01.hyp.0000042097.39655.b7

10.1056/NEJM200003303421301

10.1056/NEJM200003303421310

10.1136/bmj.321.7258.412

10.1136/bmj.317.7160.703

10.1161/circ.103.1.163

10.1001/archinte.1995.00430100105012

10.1056/NEJM199611283352203

10.1001/archopht.116.3.297

10.1056/NEJM199903043400902

10.1056/NEJMcp011773

10.1136/bmj.294.6585.1443

10.1016/S0140-6736(95)91747-0

Sowers JR, Reed J. 1999 clinical advisory: treatment of hypertension and diabetes. J Clin Hypertens (Greenwich). 2000; 2: 132–133. PR

10.1097/00005344-198500077-00016

10.1016/S0140-6736(99)12323-7

10.1016/S0140-6736(02)08090-X

10.1056/NEJM199803053381003

10.1046/j.1523-1755.2002.00213.x

10.1016/S0735-1097(02)02663-3

10.1161/01.cir.0000031732.78052.81

10.1161/hyp.37.3.869

10.1001/archinte.161.9.1207

10.7326/0003-4819-135-2-200107170-00007

10.7326/0003-4819-139-4-200308190-00006

10.1001/jama.288.19.2421

10.1001/archinte.163.9.1069

10.1161/01.str.0000064841.47697.22

10.1056/NEJM199512143332401

10.1016/S0895-7061(97)00211-2

National Heart Lung and Blood Institute. Strong Heart Study Data Book: A Report to American Indians Communities. Bethesda MD: National Institutes of Health National Heart Lung and Blood Institute. NIH Publication No. 01–3285 2001. pp. 19. http://www.nhlbi.nih.gov/resources/docs/shs_db.pdf

Crespo CJ, Loria CM, Burt VL. Hypertension and other cardiovascular disease risk factors among Mexican Americans, Cuban Americans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey. Public Health Rep. 1996; 111: 7–10.

10.1001/archinte.163.5.525

10.1001/jama.1988.03720140033030

U S Department of Health and Human Services. Understanding and improving health and objectives for improving health. Healthy People 2010. Washington DC: United States Government Printing Office; 2000. pp. 19–31.

10.1016/S0002-9343(96)00265-3

10.1001/archinte.1990.00040031707020

10.1001/archinte.160.6.825

10.1016/S0009-9236(96)90161-7

Lawrence J Stockbridge N Hung HMJ Chi G. Joint statistical-clinical review: NDA resubmission dated 14 December 2001 including the results of the OCTAVE study. FDA Center for Drug Evaluation and Research Division of Cardio-Renal Drug Products. NDA: 21–188 (omapatrilat for hypertension) June 2002. pp. 1–31. http://www.fda.gov/ohrms/dockets/ac/02/briefing/3877B2_03_FDA-Medial-Statistical.doc

10.1016/S0009-9236(96)90155-1

10.1056/NEJM199808203390801

10.1152/physrev.1995.75.3.473

10.1001/jama.289.14.1799

10.1002/1520-7560(200005/06)16:3<192::AID-DMRR114>3.0.CO;2-G

10.1161/res.85.8.753

10.1016/S0891-5849(00)00438-X

10.1007/s11892-003-0058-1

10.1007/s11906-003-0028-7

10.1097/00004872-199506000-00006

10.1001/jama.287.3.356

10.1001/archinte.163.4.427

10.1001/jama.288.21.2709

10.1016/S0002-8703(03)00227-8

10.1093/aje/kwf145

Wilson PWF, D’Agostino RB, Parise H, Meigs JB. The metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Diabetes. 2002; 51: A242. F

10.1002/j.1550-8528.1998.tb00690.x

10.2337/diacare.25.9.1612

10.1056/NEJMoa012512

10.2337/diacare.25.2007.S33

10.1001/archinte.161.13.1581

Gidding SS, Falkner B. Are we losing the game? Cardiovascular health in minority children. Ethn Dis. 2002; 12: 171–173.

10.1001/jama.286.22.2845

10.1001/jama.282.21.2027

10.1001/archinte.159.10.1104

10.1001/jama.285.11.1447

10.1001/jama.289.18.2379

10.1093/aje/kwf114

10.1006/pmed.2000.0733

Devereux R. Management of hypertensive patients with left ventricular hypertrophy and diastolic dysfunction. In: Izzo J Jr Black H (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 460–463.

10.1056/NEJM199005313222203

10.1016/S0895-7061(02)02945-X

10.1093/ajh/6.10.815

10.1093/ndt/13.3.564

10.1161/circ.91.3.698

10.1161/circ.95.8.2007

10.1056/NEJM197903293001305

10.1016/S0140-6736(87)92441-X

10.1136/bmj.303.6810.1100

10.1001/archinte.1991.00400090063012

Haynes WG Lopez JAG Mark AL. Treatment of hypertension combined with cardiovascular disease. In: Smith TW (ed): Cardiovascular Therapeutics: A Companion to Braunwald’s Heart Disease. Philadelphia PA: WB Saunders; 1996. pp. 503–504. PR

10.1016/S0140-6736(02)09327-3

Olin JW. Treatment of hypertensive patients with peripheral arterial disease. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 467–469.

10.1161/circ.81.2.2404633

U S. Census Bureau. Persons 65 Years Old and Over-Characteristics by Sex: 1980 to 2000. Statistical Abstracts of the United States: 2002. Washington DC: U S Census Bureau; 2001. pp. 43.

10.1161/hyp.35.5.1021

10.1161/hyp.26.1.60

10.1016/S0140-6736(99)07330-4

10.1016/S0140-6736(98)08127-6

10.1001/archinte.1990.00390190152026

Spence JD, Sibbald WJ, Cape RD. Pseudohypertension in the elderly. Clin Sci Mol Med Suppl. 1978; 55: 399s–402s. C

Nally J Jr. Management of renovascular hypertension. In: Izzo J Jr Black H (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 500–502.

10.1056/NEJM197308302890913

10.1001/archinte.161.5.685

10.1161/circ.98.21.2290

10.1016/S0749-0690(02)00008-3

10.1016/S0002-9343(99)00425-8

Oster JR, Materson BJ. Pseudohypertension: a diagnostic dilemma. J Clin Hypertens. 1986; 4: 307–313.

10.1016/S0140-6736(01)06226-2

10.1093/aje/153.1.72

10.1161/str.19.7.3388454

10.1161/str.22.4.2024272

10.1161/str.22.8.1866767

10.1161/str.24.6.8506547

10.1001/archneur.1995.00540330087019

10.1161/str.27.8.1274

10.1111/j.1600-0404.1996.tb00054.x

10.1212/WNL.51.4.986

10.1136/jnnp.72.6.737

10.1161/str.30.11.2440

10.1161/str.17.6.3810706

10.1148/radiology.167.2.3357964

10.1001/archneur.1991.00530180087022

10.1001/archneur.1992.00530310095018

10.1001/archneur.1995.00540340067014

10.1001/archneur.58.12.1985

10.1001/jama.281.5.438

10.1177/089198879901200102

10.1212/WNL.56.12.1683

10.1212/WNL.56.7.921

10.1016/S1052-3057(96)80013-9

10.1212/WNL.53.1.132

10.1016/S0140-6736(98)03086-4

10.1038/sj.jhh.1001095

10.1016/S0895-7061(99)00241-1

Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens. 1989; 3: 427–433. RA

10.1038/sj.jhh.1000476

Calhoun DA Oparil S. Gender and blood pressure. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 253–257. PR

10.1056/NEJMoa030808

10.1161/hyp.36.5.780

10.1001/jama.1995.03520270033028

10.1161/circ.94.3.483

10.7326/0003-4819-126-10-199705150-00002

10.1001/archinte.158.15.1681

10.1001/archinte.1996.00440040047006

Taler SJ. Treatment of pregnant hypertensive patients. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 491–493. PR

10.1016/S0140-6736(98)08049-0

10.1067/mob.2002.120080

ACOG Practice Bulletin. Chronic hypertension in pregnancy. ACOG Committee on Practice Bulletins. Obstet Gynecol. 2001; 98: 177–185. PR

10.1056/NEJM199607253350407

10.1542/peds.98.4.649

Calhoun DA. Hypertensive crisis. In: Oparil S Weber MA (eds): Hypertension: A Companion to Brenner and Recot’s The Kidney. Philadelphia PA: WB Saunders Co.; 2000. pp. 715–718. PR

Vidt DG. Management of hypertensive urgencies and emergencies. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure. Dallas TX: American Heart Association; 1999. pp. 437–440. PR

10.1111/j.1524-6175.2001.00449.x

10.1161/hyp.27.1.144

10.7326/0003-4819-139-3-200308050-00005

10.1038/sj.jhh.1001580

10.1016/S0895-7061(00)01214-0

10.1016/S0895-7061(00)01177-8

10.1016/S0090-4295(99)80191-5

10.1161/circ.105.10.1257

10.1056/NEJM199612053352301

Vidt DG. Treatment of hypertensive emergencies and urgencies. In: Izzo JL Jr Black HR Goodfriend TL (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 452–459. PR

Alper A Calhoun D. Hypertensive emergencies. In: Antman EM (ed): Cardiovascular Therapeutics: A Companion to Braunwald’s Heart Disease. Philadelphia PA: WB Saunders Co; 2002. pp. 817–831. PR

10.1067/moe.2002.123866

10.1056/NEJM199304293281704

10.1056/NEJM200005113421901

10.1001/jama.283.14.1829

10.1001/archinte.1997.00440360178019

10.1161/01.cir.0000061757.12581.15

10.1378/chest.123.1.244

10.1161/01.CIR.0000072346.56728.E4

Morgan BJ. Pathophysiology of sleep apnea. In: Izzo JL Jr Black H (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 156–158. PR

10.1172/JCI118235

10.1161/01.cir.0000018948.95175.03

10.1210/jcem.85.3.6484

10.1164/ajrccm.165.5.2104087

10.1161/circ.102.21.2607

10.1161/circ.97.21.2154

10.1056/NEJMoa022479

10.1164/ajrccm.164.12.2107045

10.1164/ajrccm.163.1.2001008

10.1161/01.cir.0000068337.25994.21

10.1161/str.27.3.401

10.1378/chest.103.5.1336

10.1378/chest.107.2.362

10.1093/aje/154.1.50

10.1001/jama.284.23.3015

10.1152/ajpheart.2000.279.1.H234

10.1161/circ.100.7.706

10.1161/hyp.35.5.1173

10.1016/S0140-6736(99)01376-8

10.1164/ajrccm.163.2.2005037

Somers VK. Management of sleep apnea. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 512–516. PR

10.1161/01.cir.0000042706.47107.7a

10.1016/S0140-6736(95)90820-X

10.1016/S0735-1097(99)00407-6

10.1161/01.hyp.0000090122.38230.41

10.1016/S0161-6420(02)01931-0

American Academy of Ophthalmology. Basic and Clinical Science Course Section 12 1999–2000. San Francisco CA: American Academy of Ophthalmology; 1999. pp. 68–70.

Textor SC. Hypertension and transplantation. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 163–165. PR

Canzanello VJ. Management of posttransplant hypertension. In: Izzo JL Jr Black HR (eds): Hypertension Primer: The Essentials of High Blood Pressure: Basic Science Population Science and Clinical Management. Philadelphia PA: Lippincott Williams & Wilkins; 2003. pp. 519–522. PR

Textor SC. Renal failure related to angiotensin-converting enzyme inhibitors. Semin Nephrol. 1997; 17: 67–76. PR

10.1038/ki.1995.281

10.4065/70.11.1041

Sos TA. Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerotic renal artery disease. Circulation. 1991; 83 (Suppl I): I-162–I-166. F

10.1016/S0140-6736(96)10093-3

10.7326/0003-4819-121-4-199408150-00011

10.1016/S0002-9343(99)00113-8

10.1016/S0002-9149(02)02661-9

10.1161/01.hyp.0000014323.99765.16

10.1097/00045391-200103000-00003

Sowers JR, White WB, Pitt B, Whelton A, Simon L, van Ingen H, et al. Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type 2 diabetes mellitus. J Am Coll Cardiol. 2003; 41: 320A. RA

10.4065/78.2.211

Herzlinger RE. Market-Driven Health Care: Who Wins Who Loses in the Transformation of America’s Largest Service Industry. Reading MA: Addison-Wesley Publishing Co; 1997. pp. 65–75 231.

10.7326/0003-4819-135-9-200111060-00012

10.1001/archinte.160.3.301

10.1016/S0749-3797(01)00356-7

10.1161/circ.93.1.4

Maue SK, Rivo ML, Weiss B, Farrelly EW, Brower-Stenger S. Effect of a primary care physician-focused, population-based approach to blood pressure control. Fam Med. 2002; 34: 508–513. F

10.1016/S0749-3797(03)00025-4

10.1007/BF03215777

10.1001/archinte.160.4.481

10.1016/S0749-3797(00)00254-3

Bandura A. Social Learning Theory. Englewood Cliffs NJ: Prentice Hall; 1977.

10.1016/S0749-3797(02)00580-9